Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ripretinib

FDA-approved product (tablet, oral), marketed as Qinlock.

Registered studies
19
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Ripretinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Gastrointestinal stromal tumor
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

19registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ripretinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ripretinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

    NCT03673501 · start 2019-02-08

    Registered record
    Registry ID
    NCT03673501
    Conditions
    Gastrointestinal Stromal Tumors
    Interventions
    Ripretinib; Sunitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2019-02-08
    Completion
    2026-12
    Enrolment
    453

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors
    InterventionRipretinib; Sunitinib
    PhasePhase 3
    Registry statusActive not recruiting

  • Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies

    NCT03353753 · start 2018-02-27

    Registered record
    Registry ID
    NCT03353753
    Conditions
    Gastrointestinal Stromal Tumors
    Interventions
    DCC-2618; Placebo Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-02-27
    Completion
    2022-05-11
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors
    InterventionDCC-2618; Placebo Oral Tablet
    PhasePhase 3
    Registry statusCompleted

  • A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

    NCT02571036 · start 2015-11

    Registered record
    Registry ID
    NCT02571036
    Conditions
    Gastrointestinal Stromal Tumors; Advanced Systemic Mastocytosis; Advanced Cancers
    Interventions
    DCC-2618; DCC-2618
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-11
    Completion
    2022-04-29
    Enrolment
    282

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors; Advanced Systemic Mastocytosis; Advanced Cancers
    InterventionDCC-2618; DCC-2618
    PhasePhase 1
    Registry statusCompleted

  • Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST

    NCT04148092

    Registered record
    Registry ID
    NCT04148092
    Conditions
    GIST - Gastrointestinal Stromal Tumor
    Interventions
    ripretinib
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    Approved for marketing
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGIST - Gastrointestinal Stromal Tumor
    Interventionripretinib
    PhaseNot recorded
    Registry statusApproved for marketing